Frankfurt - Delayed Quote EUR

Sagimet Biosciences Inc. (0O2.F)

Compare
4.8000
-0.3000
(-5.88%)
At close: January 10 at 3:29:02 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 0O2.F

Recent News: 0O2.F

View More
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
GlobeNewswire 5 days ago
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. 13 days ago
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
TipRanks 27 days ago
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire last month
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
GlobeNewswire last month
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
Simply Wall St. last month
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire last month
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
GlobeNewswire 2 months ago
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
GlobeNewswire 2 months ago
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
GlobeNewswire 2 months ago
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
GlobeNewswire 2 months ago
View More

Related Tickers

GX1.F Marker Therapeutics, Inc.
2.6200
0.00%
 
UTH.F United Therapeutics Corporation
352.30
-0.03%
 
0A9E.IL CureVac N.V.
4.3740
+1.37%
 
347850.KQ D&D Pharmatech
53,900.00
-3.92%
 
MRZM Marizyme, Inc.
0.0041
-14.58%
 
MAAT.PA MaaT Pharma SA
7.92
-12.78%
 
NVV1.F Novavax, Inc.
8.89
-6.92%
 
0QF.DE Moderna, Inc.
41.54
-1.11%
 
DMYD-B.ST Diamyd Medical AB (publ)
17.14
-5.20%
 
5CV.F CureVac N.V.
4.1500
+4.27%